These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8792482)

  • 1. Antibiotics and increased temperature against Borrelia burgdorferi in vitro.
    Reisinger E; Wendelin I; Gasser R; Halwachs G; Wilders-Truschnig M; Krejs G
    Scand J Infect Dis; 1996; 28(2):155-7. PubMed ID: 8792482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.
    Murgia R; Marchetti F; Cinco M
    Antimicrob Agents Chemother; 1999 Dec; 43(12):3030-2. PubMed ID: 10582905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.
    Pavia CS; Wormser GP; Nowakowski J; Cacciapuoti A
    Antimicrob Agents Chemother; 2001 Mar; 45(3):936-7. PubMed ID: 11181384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.
    Agger WA; Callister SM; Jobe DA
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1788-90. PubMed ID: 1416868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
    Baradaran-Dilmaghani R; Stanek G
    Infection; 1996; 24(1):60-3. PubMed ID: 8852472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic.
    Janovská D; Hulínská D; Godová T
    Cent Eur J Public Health; 2001 Feb; 9(1):38-40. PubMed ID: 11243589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lyme disease: disparity between culture and polymerase chain reaction detection of Borrelia burgdorferi after exposure to ceftriaxone in vitro.
    Varde S; Wormser GP; Nowakowski J; Nadelman RB; Bittker S; Cooper D; Schwartz I
    Conn Med; 1999 Oct; 63(10):589-91. PubMed ID: 10578549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin.
    Brouqui P; Badiaga S; Raoult D
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1552-4. PubMed ID: 8726038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi.
    Dever LL; Jorgensen JH; Barbour AG
    Antimicrob Agents Chemother; 1993 May; 37(5):1115-21. PubMed ID: 8517700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roxithromycin in the treatment of Lyme disease--update and perspectives.
    Gasser R; Wendelin I; Reisinger E; Bergloff J; Feigl B; Schafhalter I; Eber B; Grisold M; Klein W
    Infection; 1995; 23 Suppl 1():S39-43. PubMed ID: 7782115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates.
    Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
    Int J Antimicrob Agents; 2000 Jun; 15(1):11-7. PubMed ID: 10856671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.
    Kazragis RJ; Dever LL; Jorgensen JH; Barbour AG
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2632-6. PubMed ID: 8913478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.
    Dever LL; Jorgensen JH; Barbour AG
    J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of third-generation cephalosporins. Spirochetes.
    Luft B; Mariuz P
    Hosp Pract (Off Ed); 1991; 26 Suppl 4():34-9; discussion 53-4. PubMed ID: 1918214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comment on Borrelia burgdorferi Group infections].
    Bózsik BP
    Orv Hetil; 2002 May; 143(21):1223-4. PubMed ID: 12073543
    [No Abstract]   [Full Text] [Related]  

  • 16. Growth temperature ranges of Borrelia burgdorferi sensu lato strains.
    Hubálek Z; Halouzka J; Heroldová M
    J Med Microbiol; 1998 Oct; 47(10):929-32. PubMed ID: 9788818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi.
    Kersten A; Poitschek C; Rauch S; Aberer E
    Antimicrob Agents Chemother; 1995 May; 39(5):1127-33. PubMed ID: 7625800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.
    Johnson RC; Kodner CB; Jurkovich PJ; Collins JJ
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2133-6. PubMed ID: 2073103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.
    Levin JM; Nelson JA; Segreti J; Harrison B; Benson CA; Strle F
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1444-6. PubMed ID: 8363373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of an antibiotic combination on the propagation of Borrelia burgdorferi, causative agent of Lyme disease].
    Lakos A; Nagy G
    Orv Hetil; 1999 Jul; 140(27):1529-32. PubMed ID: 10436750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.